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for its protective function against the toxic effects of exoge-
nous compounds. In addition to this, a role in the transport of
endogenous compounds has been described. Since BCRP in
the plasma membrane was shown to be regulated by sex
steroids, we investigated the presence and possible role of
BCRP in steroid hormone-producing organs. Therefore, the
presence and localization of Bcrp was investigated in endo-
crine organs of wild-type mice. Furthermore, the interaction of
various steroid hormones with human BCRP activity was
studied. Quantitative PCR revealed Bcrp mRNA in the pitu-
itary and adrenal glands, pancreas, ovary, testis and adipose
tissue. Immunohistochemistry revealed the presence of Bcrp
in the cortex of the adrenal gland and in plasma membranes of
adipocytes. In the pituitary gland, pancreas, ovary and testis,
Bcrp was mainly located in the capillaries. The interaction
between BCRP and 12 steroid hormones was studied using
membrane vesicles of HEK293-BCRP cells. Estradiol, testos-
terone, progesterone and androstenedione inhibited BCRP-
mediated uptake of 3H-estrone sulphate (E1S) most potently,
with calculated inhibitory constant (Ki) values of 5.0±0.2, 36±
was attenuated non-competitively, which implies an allosteric
inhibition of BCRP-mediated E1S transport by these steroids.
In conclusion, localization of Bcrp in endocrine organs together
with the efficient allosteric inhibition of the efflux pump by
steroid hormones are suggestive for a role for BCRP in steroid
hormone regulation.
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Introduction
Breast cancer resistance protein (BCRP; ABCG2) is a member
of the ATP binding cassette (ABC) superfamily of transmem-
brane proteins involved in the transport of a variety of mole-
cules against steep concentration gradients at the expense of
ATP. BCRP is a half transporter that requires dimerization to
become a fully active efflux pump and was originally discov-
ered in a breast cancer cell line resistant to chemotherapeutics
(Mao and Unadkat 2005; Doyle et al. 1998; Ross et al. 1999).
Nowadays, BCRP is recognized as a xenobiotic transporter
that plays a major role in multidrug resistance (Jonker et al.
2005; Mao and Unadkat 2005; Doyle and Ross 2003). The
efflux pump is present in various tissues with a barrier func-
tion, including the placenta, prostate, small intestine, brain,
colon, liver, mammary gland and kidney (Maliepaard et al.
2001; Doyle and Ross 2003; Bart et al. 2004; Fetsch et al.
2006; Huls et al. 2008). In addition to the protective role of
BCRP against accumulating xenobiotic compounds, a role in
the transport of endogenous compounds has been described,
such as the transport of folic acid (Chen et al. 2003), heme
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Abstract Breast cancer resistance protein (BCRP) is known 14, 14.7±1.3 and 217±13 μM, respectively. BCRP function
(Krishnamurthy et al. 2004; Zhou et al. 2005; Suzinges-
Mandon et al. 2010), urate (Woodward et al. 2009; Matsuo
et al. 2009) and uremic toxins (Mutsaers et al. 2011). More-
over, BCRP transports conjugated steroids, such as dehydroe-
piandrosterone sulfate (DHEAS) (Lee et al. 2005), estrone
sulfate (E1S) and estradiol glucuronide (E217βG) (Chen
et al. 2003; Imai et al. 2003; Suzuki et al. 2003).
The localization of BCRP in the plasma membrane is
shown to be sex specific, which is suggested to be due to the
suppressive effect of estradiol and the inductive effect of
testosterone (Ee et al. 2004; Imai et al. 2005; Hartz et al.
2010; Tanaka et al. 2005). Also, progesterone has been shown
to regulate BCRP transcription in cancer cell lines, including
BeWo cells, a cell line derived from human placental chorio-
carcinoma (Wang et al. 2008). Moreover, a role for BCRP in
transport of androgens has been suggested in prostate stem
cells (Huss et al. 2005) and transport of estradiol was demon-
strated in membrane vesicles from Lactococcus lactis contain-
ing functional human BCRP (Janvilisri et al. 2003), indicating
that the efflux pumpmight also play a role in steroid action. In
this respect, the presence of BCRP has been described
for some hormone-producing organs (Fetsch et al. 2006;
Langmann et al. 2003; Tanaka et al. 2005) but for some
organs, only BCRP mRNA content or presence of the protein
by western blot has been shown. In the present study, we
investigated murine organs, including the pituitary and adre-
nal glands, pancreas, kidney, ovary, testis and adipose tissue,
for the presence and localization of Bcrp. Furthermore, we
evaluated the effects of several sex steroids on BCRP-
mediated substrate transport using membrane vesicles of
baculovirus-transduced HEK293 cells. Our results show the
presence of the efflux pump in steroid-producing organs. In
addition, the sex steroids estradiol, testosterone, progesterone
and androstenedione inhibited BCRP function in a
concentration-dependent manner.
Materials and methods
RNA isolation and quantitative PCR
All procedures involving animals were approved by the An-
imal Experimental Committee of the Radboud University
Nijmegen Medical Centre. Bcrp mRNA was assessed in the
adrenal gland, pituitary gland, epididymal fat pad, abdominal
fat pad, pancreas, testis, ovary and kidney of Friend leukemia
virus B (FVB) mice (Charles River Laboratories, Germany).
Isolated organs were immediately snap-frozen in liquid nitro-
gen until further analysis. Fat pads, adrenal glands and
pituitaries were homogenized using micropestles. Other
organs were homogenized in frozen state using a Mikro-
dismembrator U (Sartorius B. Braun Biotech, Melsungen,
Germany). To avoid RNA degradation, the metal cylinders
were washed with 0.5 M NaOH prior to use. Subsequently,
total RNA was isolated using a NucleoSpin® RNA II kit
(Macherey-Nagel, Düren, Germany) according to the manu-
facturer’s instructions. Immediately, a reverse transcriptase
reaction was performed with 250 ng RNA using random
primers (Invitrogen, Breda, The Netherlands) and an Omni-
script® RT kit (Qiagen, Hilden, Germany), following the
manufacturer’s recommendations. Synthesized cDNA was
used for quantitative PCR, performed in a StepOnePlus™
Real-Time PCR system by means of the TaqMan® protocol
(Applied Biosystems, Warrington, UK). BcrpmRNA concen-
tration was normalized to the mRNA concentration of the
housekeeping gene ß-actin. The primer-probe sets were
obtained fromApplied Biosystems (β-actin: 4352933E; Bcrp:
Mm00496364_m1).
Immunohistochemistry
The localization of Bcrp was assessed by immunohistochem-
istry. Organs from Bcrp−/− mice were used as negative con-
trols. The knockout mice were kindly provided by Dr. A.
Schinkel (Netherlands Cancer Institute, Amsterdam, The
Netherlands) and were bred and housed at the Central Animal
Laboratory of the Radboud University Nijmegen Medical
Centre. The organs were fixed by cardiac perfusion. Briefly,
the mice were anesthetizedwith a single, lethal i.p. injection of
100 mg/kg pentobarbital (Nembutal, 60 mg/ml). The hearts of
anesthetized mice were exposed and the right atrium was
clipped with surgical scissors. A 23-gauge needle was inserted
into the left ventricle and phosphate buffered saline (PBS)
containing heparin (300 ml/h) was administered. Subsequent-
ly, the mice were perfused with a 4 %w/v formaldehyde
solution, freshly prepared from paraformaldehyde. The organs
were removed and fixed in a 4 %w/v formaldehyde solution
for 24 h and embedded in paraffin, except for the fat at pads,
which were fixed in Bouin’s fixative immediately after the
perfusion fixation. Sections of 5 μm were mounted on 3-
aminopropyltriethoxysilane (APES)-coated slides and dried
for 2 h at 57 °C. After deparaffinization with xylene and
rehydration, the slides were heated in sodium citrate buffer
(pH 6) at 100 °C for 15 min. Endogenous peroxidase was
blocked with 1.5 %v/v H2O2 for 30 min. After blocking with
nonimmune rabbit serum, the slides were incubated with
primary antibody against mouse Bcrp (BXP-9, 1:20; Kamiya
Biomedical, Seattle, WA, USA) overnight at 4 °C. The bio-
tinylated secondary antibody (rabbit anti rat, 1:500; Acris
Antibodies, Herford, Germany) was incubated for 30 min
followed by a 30-min incubation with standard avidin-biotin
complex (ABC; Brunschwig Chemie, Amsterdam, The Neth-
erlands). Next, DAB chromogene was used for visualization.
Slides were counterstained with Mayer’s hematoxylin, dehy-
drated and mounted with DPX. Sections were evaluated by
means of a light microscope (Leica DM 6000 B) and digitized
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using a Leica DFC480 digital camera (Leica Microsystems,
Wetzlar, Germany).
Transduction of human embryonic kidney (HEK293) cells
and isolation of membrane vesicles
Increased synthesis of human BCRP and MRP3 in HEK293
cells was established using baculoviruses, which were pro-
duced using the Bac-to-Bac system (Invitrogen, Breda, The
Netherlands) with BacMamVSV-EX-hBCRP (pENTR221-
hBCRP; HsCD00044371; Harvard Institute of Proteomics,
Harvard Medical School, Boston, MA, USA) and
BacMamVSV-EX-hMRP3 (sequence of MRP3 was equal
to GenBank accession number NM_003786), as described
previously by Wittgen et al. (2011). As a control, the en-
hanced yellow fluorescent protein (eYFP) was also introduced
into the baculoviruses.
Crude membranes of HEK293-BCRP, -MRP3 and
-eYFP cells were isolated, resuspended in TS buffer
(10 mM Tris-HEPES and 250 mM sucrose, pH 7.4) and
membrane vesicles were prepared according to a previously
described method (El-Sheikh et al. 2007). Total protein
concentration was determined by a Bio-Rad protein assay
Western blot analysis
Membrane vesicles were prepared for gel electrophoresis by
incubation with Laemmli sample buffer (consisting in 0.5 M
Tris–HCl pH 6.8, 8 %w/v sodium dodecyl sulfate (SDS),
40 %w/v glycerol, 0.08 %w/v bromophenol blue and 0.4 M
ß-mercapto-ethanol) for 10 min at 65° C. Proteins (15 μg total
protein per sample) were separated by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) using a 10 % gel and blotted
onto a nitrocellulose membrane using a dry blot system (iBlot;
Invitrogen). The membrane was incubated overnight at 4 °C
with mouse-anti-hBCRP antibody (BXP-21, 1:200; Kamiya
Biomedical) or mouse-anti-hMRP3 antibody (M3II-21, 1:200;
Abcam, Cambridge, UK). Primary antibodies were detected
using fluorescently labeled goat-anti-mouse secondary anti-
body (IRdye800; 1:10,000 Rockland Immunochemicals,
Boyertown, PA, USA). Signals were visualized using the
Odyssey imaging system (Li-Cor Biosciences, Lincoln, NE,
USA).
BCRP-mediated estrone sulfate (E1S) uptake and inhibition
by steroids
Uptake of [3H]-E1S into HEK293-BCRP and -eYFP mem-
brane vesicles was performed using an assay that was well
established in our laboratory (El-Sheikh et al. 2007; Mut-
saers et al. 2011; Wittgen et al. 2011). A reaction mix
consisting in a TS buffer supplemented with 4 mM ATP/
AMP, 10 mM MgCl2 and various concentrations of [
3H]-
E1S at pH 7.4 was added to 7.5 μg of membrane vesicles
(based on total protein content). After an incubation of 60 s
at 37 °C to enable ATP-dependent uptake, the reaction was
stopped by placing the samples on ice and by addition of an
ice-cold TS buffer. The reaction mix was removed and the
vesicles were washed by means of a rapid filtration tech-
nique using glass fiber filter plates (Millipore, Etten-Leur,
The Netherlands). Scintillation fluid was added to the filters
and the amount of radioactivity was determined using a
scintillation counter (Tri-Carb® 2900TR; Perkin Elmer,
Waltham, MA, USA). Reference samples were measured
to calculate the amount of transported E1S. ATP-dependent
transport was calculated by subtracting values measured in
the presence of AMP from those measured in the presence
of ATP. Net BCRP-mediated E1S transport was calculated
by subtracting ATP-dependent E1S uptake in HEK293-
eYFP vesicles from that of HEK293-BCRP vesicles. Line-
arity of E1S uptake in time was determined using 250 nM
E1S.
The effects of several androgens, estrogens and proges-
tagens (all obtained from Sigma-Aldrich, St. Louis, MO,
USA or Steraloids, Newport, RI, USA) on vesicular E1S
uptake were assessed by performing the above-mentioned
transport assay in the presence of 50 μM of the steroid. All
steroid hormones were dissolved in ethanol. Maximum eth-
anol concentrations of 1.3 %v/v were used in uptake experi-
ments and solvent controls were included to exclude non-
specific effects. The inhibition by the steroid hormones
estradiol, testosterone, progesterone and androstenedione
on vesicular E1S uptake was studied in more detail. There-
fore, the membrane vesicles were incubated in the presence
of increasing concentrations of the steroid at three different
concentrations of [3H]-E1S (50, 100 and 250 nM). In studies
with androstenedione, the glass fiber filter plate was pre-
incubated with 50 mg/ml BSA for 1 h at 37 °C and the
reaction mix was supplemented with 0.2 mg/ml BSA, to
reduce the background that is caused by adhesion to the
filter plate. The sidedness of the membrane vesicles was not
determined as ATP-dependent uptake can occur only in
inside-out vesicles. The relative inhibition by steroids was
expressed as a percentage of maximum uptake.
Inhibition of MRP3-mediated estradiol glucuronide
(E217βG) uptake by steroids
The effects of estradiol, testosterone, progesterone and
androstenedione on MRP3 activity was determined by the
same method as described above, using E217βG as a sub-
strate. HEK293-eYFP and -MRP3 membrane vesicles were
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kit (Bio-Rad Laboratories, Veenendaal, The Netherlands).
Crude membrane vesicles were dispensed in aliquots,
snap-frozen in liquid nitrogen and stored at −80 °C until
further use.
incubated with 80 nM [3H]-E217βG with or without the
steroids, for 3 min at 37 °C. The washing steps were per-
formed using PVDF filter plates (Millipore). These parameters
were adapted from Wittgen et al. (2011). Unlabeled E217βG
(100 μM) was used as a positive control for inhibition of
MRP3 activity.
Data analysis
Relative Bcrp mRNA concentration was normalized for the
cycle threshold (Ct) value of the endogenous reference gene
β-actin (delta Ct; dCt) and depicted as the reciprocal of dCt
(mean ± SEM). Differences in mRNA concentration between
male and female organs were assessed bymeans of a Student’s
t test, considering P<0.05 significant. Fold differences in
Bcrp mRNA levels between the organs were calculated using
2(dCt organ1-dCt organ2). Uptake experiments were performed in
triplicate in three independent batch isolations. Michaelis–
Menten analysis was used to study transport kinetics. Inhibi-
tion curves are depicted as mean±SEM of three independent
experiments. Curve fitting was performed by non-linear re-
gression analysis. The mode of inhibition was determined
using Dixon’s method combined with linear regression anal-
ysis to estimate the inhibitory constant (Ki). A representative
of one experiment is depicted. Differences inMRP3-mediated
E217βG uptake were assessed by means of a one-way
ANOVA test followed by Dunnett’s post hoc test. All analyses
were performed with GraphPad Prism software (v.5.02;
GraphPad Software, San Diego, CA, USA).
Results
Bcrp mRNA analysis in murine organs
Bcrp mRNA levels in murine endocrine organs were deter-
mined by means of quantitative PCR (Fig. 1). For compar-
ison, mRNA levels in kidneys were evaluated, which are
known to be very high (Huls et al. 2008). The relative Bcrp
mRNA concentration was normalized to the mRNA con-
centration of the endogenous reference gene β-actin. The
variation in cycle threshold (Ct) values of β-actin indicated
that the QPCR reactions were reproducible (SEM ≤ 0.92).
Bcrp mRNA was present in all organs tested. The relative
mRNA concentration in the adrenal gland, pituitary gland,
epididymal and abdominal fat, the pancreas and the ovary
was comparable and found to be more than 30 times lower
as compared to mRNA levels in the kidney. Bcrp mRNA
levels in the testis was about four times higher than in the
other organs but 9-fold lower as compared to the kidney.
Interestingly, mRNA levels of Bcrp in male mice were
slightly higher than in female mice (P<0.01 for the kidney
and P<0.05 for other organs), while there was no difference
in β-actin mRNA concentration between samples from
males and females.
Localization of Bcrp in murine organs
Immunohistochemical analysis revealed localization of Bcrp
protein in numerous murine organs. Organ sections of
Bcrp−/− mice were used to determine nonspecific staining.
Both male and female organ sections were evaluated but no
differences in localization of the protein between male and
female were found (data not shown). Therefore, only organs
from female mice are shown here, except for the testis.
Fig. 2 depicts Bcrp localization in organs with a barrier
function, viz. kidney, brain and liver. In the kidney, Bcrp
staining was most prominently observed in the proximal
tubular lumen, the brush border (Fig. 2a). Also, Bcrp was
localized in Bowman’s capsule brush border, which is pres-
ent in murine nephrons. The distal tubular lumen did not
contain Bcrp. No Bcrp staining was found in the negative
control sections (Bcrp−/−; Fig. 2c, d, g, h, k, l). Furthermore,
Bcrp was localized in the capillaries of the brain and liver
(Fig. 2e, f, and i, j, respectively). Besides presence of Bcrp
in organs with a barrier function, the protein was found in
endocrine organs (Figs. 3 and 4). Bcrp was clearly localized
in the sinusoidal capillaries in the adrenal gland cortex
(Fig. 3a–d). In addition to this, some cells showed intracel-
lular Bcrp staining in the zona glomerulosa (Fig. 3a) and
zona reticularis (Fig. 3c) but intracellular Bcrp staining was
not found in either the zona fasciculata (Fig. 3b) or the
Fig. 1 Relative BcrpmRNA concentration in wild-type mouse organs,
normalized for the cycle threshold (Ct) value of the endogenous
reference gene β-actin (delta Ct; dCt). For all experiments, tissues
from six mice were individually analyzed, except for the adrenal gland
and the pituitary gland. For those, three samples of two pooled organs
were analyzed. Bars represent the reciprocal of mean dCt ± SEM of
independent experiments (n 0 3–6). *P<0.05; **P<0.01 compared to
Bcrp mRNA concentration in males by Student’s t test. There was no
difference in β-actin mRNA concentration between males and females.
The SEM of β-actin Ct values was≤0.92
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medulla of the adrenal gland (Fig. 3d). In the capillaries of
the anterior pituitary gland, Bcrp was localized at the apical
surface of the endothelial cells (Fig. 3g, h). The hormone
producing cells of the pituitary gland showed no Bcrp-
specific staining. The adipocytes in both epididymal and
abdominal fat pads showed Bcrp positivity, which was
absent in Bcrp−/− sections (Fig. 3k, l). No differences in
localization of the pump were found between epididymal
and abdominal fat pads and therefore only micrographs of
epididymal fat pads are shown in Fig. 3k, l. Bcrp was not
located in the endocrine and exocrine cells of the pancreas
(Fig. 4a, b) but endothelial cells lining the lumen of the
capillaries in the pancreas showed a very subtle Bcrp stain-
ing (Fig. 4a), when comparing wild-type organs with the
negative control organs. Blood vessels of the testis, located
between the seminiferous tubules, were Bcrp-positive
Fig. 2 Representative
immunohistochemical images of
Bcrp distribution in wild-type
and Bcrp−/− (negative control)
mouse kidney (a–d), brain tissue
(e–h) and liver (i–l). Because of
an absence of gender difference
in localization, only organs from
female mice are shown.
Perfusion-fixed, paraffin embed-
ded organ sections were incu-
bated with a primary antibody
against mouse Bcrp (BXP-9).
DAB chromogene staining
(brown) visualizes Bcrp locali-
zation. The sections were coun-
terstained with Mayer’s
hematoxylin. Bars 100 μm in
(b, d, f, h, j, l). a, e, i represent
details of Bcrp positivity and
corresponding negative controls
(c, g, k); bars in these insets
50 μm. Bcrp was present in the
brush border of proximal tubule
and in the brush border of Bow-
man’s capsules (arrow) of the
kidney and in the capillaries of
the brain and liver
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(Fig. 4e, f). On the other hand, the interstitial cells of Leydig
and the Sertoli cells, which were located within the semi-
niferous tubules, did not show Bcrp staining. Furthermore,
the transport protein was localized in endothelial cells lining
the lumen of ovarian blood vessels (Fig. 4i, j). Interestingly,
not all vessels were Bcrp-positive but Bcrp was present in
all small capillaries.
Presence and activity of BCRP in isolated membrane
vesicles
Increased synthesis of human BCRP in HEK293 cells was
established by transduction with baculovirus containing the
recombinant bacmide DNA. Western blot analysis performed
on isolated membrane vesicles demonstrated that the trans-
duction was successful, as indicated by the band at ~75 kD
(Fig. 5a). The negative control, consisting in membrane
vesicles isolated from HEK293-eYFP cells, showed no pres-
ence of BCRP. Transport activity was determined by incubat-
ing the membrane vesicles with [3H]-E1S at 37 °C. Time-
dependent uptake showed linearity up to 120 s (data not
shown). Michaelis–Menten analysis (Fig. 5b) revealed a Km
of 4.5±0.4 μM and a Vmax of 332±12 pmol/mg min−1, after
incubating the vesicles for 60 s at 37 °C. In control (eYFP)
vesicles, a maximum uptake rate of 6 pmol/mg min−1 was
found.
Inhibition of transport activity of BCRP and MRP3
by steroids
The effects of several androgens, estrogens and progestagens
on BCRP-mediated E1S uptake was assessed by incubating the
membrane vesicles with [3H]-E1S in the presence of 50 μM of
the steroid for 60 s at 37 °C. A substrate concentration of
Fig. 3 Representative
immunohistochemical images of
Bcrp distribution in wild-type
and Bcrp−/− (negative control)
mouse adrenal gland (a–f), pitu-
itary gland (g–j) and epididymal
fat (k–n). Because of an absence
of gender difference in localiza-
tion, only organs from female
mice are shown. Perfusion-fixed,
paraffin embedded organ-
sections were incubated with a
primary antibody against mouse
Bcrp (BXP-9). DAB chromo-
gene staining (brown) visualizes
Bcrp localization. The sections
were counterstained with
Mayer’s hematoxylin. Bars
100 μm for adrenal gland (d, f)
and 50 μm for pituitary gland
(h, j) and epididymal fat (l, n).
Details of Bcrp positivity in a
zona glomerulosa, b zona fasci-
culata, c zona reticularis of the
adrenal gland and corresponding
negative controls (e) are indicat-
ed with a bar of 50 μm. g, k
represent details of Bcrp positiv-
ity and corresponding negative
controls (i, m) in pituitary gland
and epididymal fat; bars in these
insets 25 μm. Bcrp was located
in the sinusoidal capillaries in
adrenal gland cortex, in the cap-
illaries of the pituitary gland and
in adipocytes
556 Cell Tissue Res (2012) 349:551–563
250 nM E1S was used (Fig. 5b), which was well below the Km
of E1S uptake to ascertain initial uptake kinetics. Estradiol,
testosterone, progesterone and androstenedione inhibited the
efflux pump most potently (Table 1) and were, therefore, se-
lected to be studied in more detail. Concentration-dependent
inhibition of BCRP-mediated uptake of E1S was found for all
four steroids (Fig. 6a–d). Progesterone was able to inhibit
BCRP activity for >90%within the concentration-range tested.
Estradiol, testosterone and androstenedione inhibited the efflux
pump for 80, 86 and 70 %, respectively, at the highest possible
concentrations tested. We were not able to assess whether the
steroids were able to fully inhibit the efflux pump using our
vesicular transport system because this was limited by the
maximum solubility of the steroids in ethanol.
Because of their lipophilicity, steroids move readily
through the plasma membrane and potentially might interfere
Fig. 4 Representative
immunohistochemical images
of Bcrp distribution in
wild-type and Bcrp−/− (negative
control) mouse pancreas
(female, a–d), testis (e–h) and
ovary (i–l). Perfusion-fixed,
paraffin embedded organ-
sections were incubated with a
primary antibody against mouse
Bcrp (BXP-9). DAB chromo-
gene staining (brown) visual-
izes Bcrp localization. The
sections were counterstained
with Mayer’s hematoxylin.
Bars 100 μm (b, d, f, h, j, l).
a, e, i represent details of Bcrp
positivity and corresponding
negative controls (c, g, k); bars
in these insets 50 μm. Blood
vessels in the testis and ovary
showed distinct Bcrp positivity,
whereas in the pancreas, they
showed very subtle Bcrp
staining
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with other membrane transporters. To exclude the possibility
that the inhibitory effects on BCRP activity resulted from such
a nonspecific phenomenon, the steroids were tested for their
inhibitory effects on the activity of another ABC transporter,
viz.MRP3. Unlike substrates for other ABC transporters, such
as MRP1, MRP2 and P-glycoprotein, MRP3 substrates do not
overlap with the ones known to be transported by BCRP.
Because of this, we did not expect steroids to interact with
MRP3. Increased synthesis of human MRP3 in HEK293
membranes was confirmed using western blot analysis
(Fig. 7a). Concentrations of the steroids that were able to
inhibit BCRP activity for more than 50 % were used to
determine their effects on MRP3 activity, using E217βG as a
substrate. Under these conditions, none of the steroids
inhibited MRP3-mediated [3H]-E217βG uptake (Fig. 7b). In-
stead, testosterone and progesterone even stimulated MRP3
activity. Moreover, the positive control, unlabeled E217βG
(100 μM), did inhibit [3H]-E217βG uptake significantly, to
19.4±0.6 % of maximum uptake (P<0.001).
Dixon plot analysis
To determine the mode of interaction, we measured
concentration-dependent effects of the steroids on BCRP
activity at three different E1S concentrations. Fig. 8a–d
depicts Dixon plots of the data, which were analyzed by
linear regression. The three lines representing steroid inhi-
bition at different E1S concentrations of the four steroids all
intersected at the x-axis, indicating a non-competitive inhib-
itory effect. The apparent inhibitory constant (Ki) values
were 5.0±0.2 μM for estradiol, 36±14 μM for testosterone,
14.7±1.3 μM for progesterone and 217±13 μM for
androstenedione.
Discussion
This study reports a clear overview of Bcrp presence in
several murine organs as well as its cellular localization in
these tissues. In addition to adrenal gland, pancreas and
testis, we show for the first time localization of Bcrp in
ovary, pituitary gland and adipose tissues. Moreover, we
report an efficient inhibitory effect of steroid hormones on
Fig. 5 aWestern blot analysis of
HEK293-eYFP- and -BCRP
membrane vesicles. BCRP was
detected using mouse-anti-BCRP
antibody (BXP-21). A Michae-
lis–Menten plot (b) revealed net
BCRP-mediated uptake of E1S.
Vesicles were incubated with in-
creasing concentrations of [3H]-
E1S for 60 s at 37 °C in the pres-
ence of AMP or ATP. Net ATP-
dependent uptake was calculated
by subtraction of AMP values.
Control (eYFP) vesicles showed
maximum uptake of 6 pmol/mg
min−1. Graph represents means ±
SEM of triplicate measurements
in a representative experiment
Table 1 Effect of steroids (50 μM) on BCRP-mediated vesicular
E1S uptake
Steroid Vesicular E1S uptake (%)
Cholesterol 71.9±5.2
Pregnenolone ND
17α-hydroxypregnonolone 77.2±17.1
Dehydroepiandrosterone 58.7±7.8
Androstenediol 70.2±18.7
Progesterone 28.7±14.4a
17α-hydroxyprogesterone 108.0±18.7
Androstenedione 42.4±9.4a
Testosterone 20.1±12.2a
Dihydrotestosterone 48.4±24.6
Estrone ND
Estradiol 40.4±8.4a
Estriol 53.1±22.5
Values are shown as mean ± SEM of one experiment performed in
triplicate. Vesicular E1S uptake is expressed as a percentage of maxi-
mum uptake after incubation with 250 nM [3 H]-E1S with or without
50 μM of the steroid for 60 s at 37 °C
ND Not determined
a The most potent inhibitors of BCRP-mediated E1S uptake were
selected to be studied in more detail
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BCRP function. Estradiol, testosterone, progesterone and
androstenedione attenuated BCRP-mediated E1S transport
in a non-competitive manner, which implies an allosteric
inhibition of BCRP function by these steroids.
Presence of BCRP in various tissues with a barrier func-
tion, including placenta, prostate, small intestine, brain,
colon, liver, mammary gland and kidney has been shown
previously (Maliepaard et al. 2001; Doyle and Ross 2003;
Bart et al. 2004; Fetsch et al. 2006; Huls et al. 2008).
Investigations on the presence of the efflux pump in endo-
crine organs has received much less attention and localiza-
tion of the protein has hardly been described. We assessed
Bcrp on both mRNA level and protein presence in endocrine
organs. In addition, endocrine organs from Bcrp−/− mice
were used for comparison, allowing discrimination between
background and Bcrp-specific staining. In accordance with
the findings of Langmann et al. (2003), who quantified Bcrp
mRNA in various human tissues, we found Bcrp mRNA in
mouse kidney, testis and adrenal gland. While our results
show highest mRNA levels in the kidney, Langmann et al.
described highest mRNA levels in the testis. This could be
attributed to interspecies differences. We have previously
described that Bcrp mRNA levels were much higher in
mouse kidneys compared to rat and human kidneys (Huls
et al. 2008). Additionally, our results revealed that, for all
organs tested, mRNA concentrations of Bcrp in male mice
were significantly higher than in females, which is in agree-
ment with previously published findings. Despite the clear
gender differences in Bcrp mRNA levels, there were no
differences in localization of the protein between male and
Fig. 6 Concentration-
dependent inhibition of net
BCRP-mediated E1S uptake by
estradiol (a), testosterone (b),
progesterone (c) and androste-
nedione (d). Vesicles were in-
cubated with 250 nM [3H]-E1S
and increasing concentrations
of the steroid, for 60 s at 37 °C
in the presence of AMP or ATP.
AMP values were subtracted
from ATP values. Net BCRP-
mediated E1S uptake was cal-
culated by subtraction of
corresponding eYFP values and
expressed as a percentage of
maximum uptake. Curve fitting
was performed by non-linear
regression analysis. Graphs
represent means ± SEM of three
independent experiments
Fig. 7 aWestern blot analysis of HEK293-eYFP- and -MRP3 membrane
vesicles. MRP3 was detected using mouse-anti-MRP3 antibody (M3II-21).
b Effects of estradiol, testosterone, progesterone and androstenedione on
MRP3 activity. Membrane vesicles were incubated with 80 nM [3H]-
E217βG (substrate) and indicated concentrations of the steroids, for
3 min at 37 °C. The effect of the steroids on net MRP3-mediated
E217βG uptake is expressed as a percentage of uptake in negative control
samples. Bars represent means ± SEM of three independent experiments.
Differences inMRP3-mediated E217βG uptake were assessed by means of
a one-way ANOVA test followed by Dunnett’s post hoc test
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female organs (data not shown). Tanaka et al. (2005) de-
scribed male-predominant Bcrp gene expression in rat kid-
ney and mouse liver. Moreover, Merino et al. (2005) found
differences in the disposition of the BCRP substrate, nitro-
furantoin, between male and female mice, with higher plas-
ma levels in females. They also reported higher hepatic
protein levels of human BCRP in men compared to women,
determined by western blot analysis using crude membrane
fractions from human liver. The precise role of the efflux
pump in males versus females was beyond the scope of the
present study and further research should elucidate the con-
sequences of this gender difference.
In accordance with previous findings (Huls et al. 2008),
immunohistochemical analysis revealed that Bcrp was prom-
inently located in the brush borders of proximal tubule epi-
thelium of the murine kidney. Furthermore, Bcrp was found to
be present in the adrenal gland, pituitary gland, testis and
ovary, where it was located predominantly in endothelial cells
lining blood vessel walls. In agreement, Maliepaard et al.
(2001) reported Bcrp localization in venous and capillary
endothelial cells of almost all tissues.
In addition to the arterioles in the adrenal gland cortex,
Bcrp was found to be present in the cells lining the zona
glomerulosa and zona reticularis, which secrete mineralo-
corticosteroids and androgens, respectively. The latter is in
agreement with the findings of Fetsch et al. (2006). For the
pituitary gland, we are the first to reveal Bcrp localization in
the capillaries. Bcrp presence in blood vessels was also
found in the pancreas, though it was low compared to the
other organs studied. The presence of Bcrp in the pancreas
has been described previously but mainly in pancreatic
progenitor cells (Mato et al. 2009; Zhang et al. 2005). In
contrast to Fetsch et al. (2006), who reported Bcrp
localization in the islet and acinar cells, we did not find
Bcrp in the endocrine and exocrine cells of the pancreas.
In ovary, Bcrp was clearly present in capillaries and some
larger blood vessels and the capillaries also showed positive
staining in the testis. The fact that not all vessels in ovary
tissue were Bcrp-positive might be characteristic for the dy-
namic environment of the estrous cycle, where there is a
constant regeneration and degradation of capillaries. The
degrading capillaries lose their endothelial function and there-
by endothelial protein is decreased. Tanaka et al. (2005)
reported Bcrp in ovary and testis of mice. In accordance with
our results, they demonstrated that Bcrp protein levels were
higher in testis than in ovary. Enokizono et al. (2007) did not
find evidence for Bcrp activity when evaluating genistein
accumulation in the ovaries of wild-type and Bcrp−/− mice
but they did find Bcrp activity in murine testis. It was reported
that the interstitial cells of Leydig (Fetsch et al. 2006) and
spermatogonial cells (Lassalle et al. 2004) of the testis local-
ized Bcrp. Conversely, our findings could not endorse these
reports. However, the presence of Bcrp in the lumina of
testicular blood vessels was evident (Bart et al. 2004).
In both epididymal and abdominal fat pads, we found Bcrp
to be present in mature adipocytes, which has not previously
been described. Adipocytes are metabolically active cells that
play a key role in the control of the body's energy balance by
the secretion of resistin, adiponectin and leptin. Moreover,
adipocytes are involved in steroid hormone regulation since
they highly express aromatase (CYP19A1), which is respon-
sible for a key step in the biosynthesis of estrogens (Raven et
al. 2006). Therefore, it will be interesting to further unravel the
role of Bcrp in adipocytes.
Another important endocrine organ, which we did not
evaluate, is the mammary gland. Steroids greatly influence
Fig. 8 Dixon plots of inhibitory
effects of estradiol (a),
testosterone (b), progesterone (c)
and androstenedione (d) on
BCRP-mediated E1S uptake.
Membrane vesicles were incu-
bated with indicated concentra-
tions of [3H]-E1S and increasing
concentrations of the steroid. The
reciprocal of transport velocity
(1/V) was calculated and the
mode of inhibition was deter-
mined using Dixon’s method
combined with linear regression
analysis to estimate the inhibitory
constant (Ki) values; a 5.0±
0.2 μM; b 36±14 μM; c 14.7±
1.3 μM; d 217±13 μM). A rep-
resentative of one experiment, out
of three independent measure-
ments, is depicted
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the growth and function of the mammary gland. It is, there-
fore, interesting to study the presence and function of Bcrp
in this organ. In 2005, Jonker et al. (2005) published the
localization of BCRP/Bcrp in breast tissue of mice, cows and
humans. They clearly showed that the transporter was local-
ized in mouse mammary gland epithelium during late preg-
nancy and in lactating mice but presence of the protein was
negligible in the mammary gland of nonpregnant and non-
lactating mice. It would be interesting to study the mechanism
by which Bcrp synthesis and function is influenced during
pregnancy and lactation.
In all the organs we analyzed, Bcrp was principally found
in the endothelial layer of sinusoids, capillaries and veins.
The fact that Bcrp was located in the canalicular membrane
of the liver indicates that the efflux pump may be involved
in excretion processes in the liver, similar to other ABC
transporters, such as P-gp and MRP2 (Maliepaard et al.
2001). In the brain and the testis, the endothelial cells form
tight junctions, creating a blood–tissue barrier, preventing
substances from freely entering the tissue. Here, efflux
transporters, such as Bcrp, are thought to protect the brain
and developing sperm cells against toxic agents. In other
organs, normal endothelium consists in loosely connected
endothelial cells and is known to be quite permeable for
several substances. Nevertheless, the fact that Bcrp is so
clearly present in these endothelial cells and that it is able to
transport substances against a concentration gradient indicates
a contribution of the efflux pump to transport compounds
across the endothelium. Although, the endocrine organs, ob-
viously, have a significant secretory function, we did not find
Bcrp localized in endocrine and exocrine cells, except for
adipocytes and the adrenal gland. Hence, the efflux pump
may contribute to the transport of steroids, or their derivates,
into the blood stream.
Using Dixon’s method, we proved indirectly that estra-
diol, testosterone, progesterone and androstenedione are
efficient inhibitors but likely not transported by BCRP via
the same binding site as E1S. The question whether steroids
are substrates for BCRP has been discussed before and
contradictory findings have been reported (Huss et al.
2005; Imai et al. 2003; Janvilisri et al. 2003). Most studies
support the conclusion that steroids interact but are not
substrates for BCRP, which is in agreement with the present
findings. Nevertheless, we cannot completely rule out the
possibility of steroids being transported by BCRP. The idea
that there is no need for steroids to be transported actively
over the plasma membrane because of their high lipophilic-
ity is outdated, since it has been described that steroids are
substrates for other ABC transporters (van Kalken et al.
1993; Drobnik et al. 2001; Wolf and Horwitz 1992; Dikkers
and Tietge 2010). Besides, steroids are derived from cho-
lesterol, which itself is transported by other members of the
ABCG subfamily (Graf et al. 2003; Schmitz et al. 2001). We
have undertaken studies to measure steroid uptake in
HEK293-BCRP membrane vesicles but unreliable results
were obtained due to the large passive permeability of these
lipophilic compounds.
To exclude the possibility that the inhibitory effects
of the steroids on BCRP activity were nonspecific, their
effects on the activity of MRP3 was tested. None of the
steroids inhibited MRP3-mediated E217βG uptake. In-
terestingly, however, testosterone and progesterone stim-
ulated this uptake. Stimulation of MRP3 has been described
before, although the mechanism explaining these complex
stimulatory effects has not yet been elucidated (Akita et al.
2002; Chu et al. 2004;Wittgen et al. 2011). The fact that MRP3
function was not inhibited by the steroids indicates that the
inhibition of BCRP activity by the steroids was a transporter-
specific effect.
Estradiol, testosterone, progesterone and androstenedione
inhibited BCRP activity by more than 70 %. However, the
concentrations needed to cause this inhibitory effect were
rather high compared to plasma levels. These concentrations
are indicative of the affinity of the steroids for BCRP com-
pared to the affinity of the substrate (E1S) for BCRP, which is
known to be very high. When the affinity of the steroids is
much lower, then the concentrations needed to cause an effect
are obviously much higher. Furthermore, the steroids them-
selves are very lipophilic and are therefore prone to stick to
plastic tubes and/or wells, which might result in an over-
estimation of the actual concentration. This problem was
acknowledged earlier by Tanneberger et al. (2010). To predict
the clinical relevance of the interaction between steroids and
BCRP, knowledge on intracellular steroid concentrations is
important. Plasma steroid levels are not relevant for predicting
their effects on a membrane transporter that transports mole-
cules from the inside to the outside of the cell. Intracellular
levels are, so far, unknown and difficult to determine. One can
imagine that intracellular concentrations in organs responsible
for the production of hormones may be much higher than
plasma levels and, thereby, could potentially influence BCRP
function in vivo.
Not only BCRP function is altered by steroids, as shown
in our results but membranal localization of BCRP is also
highly influenced by sex steroids. Imai et al. (2005) found
that estrogens post-transcriptionally downregulated BCRP
in estrogen-responsive cancer cells. They found estradiol-
mediated reduction in BCRP protein in MCF-7 cells but not
on the mRNA level. This downregulation was counteracted
by gene silencing of estrogen receptor-α (ERα), indicating
that ERα is necessary for the suppression of BCRP protein.
In agreement, Hartz et al. (2010) described that estradiol
signals through ERβ and ERα to initiate Bcrp internaliza-
tion and acts via ERβ to stimulate proteosomal degradation
of Bcrp in murine brain capillaries. In contrast, Ee et al.
(2004) found that estradiol enhanced Bcrp mRNA levels in
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cells stably expressing ERα, at similar estradiol concentra-
tions. Ovariectomy and castration of mice and rats, solely or in
combination with sex steroid treatment, revealed regulation of
Bcrp mRNA by estradiol and testosterone (Tanaka et al.
2005). In human placental BeWo cells, progesterone and
estradiol significantly increased and decreased BCRP mRNA
levels, respectively (Wang et al. 2006). Estradiol by itself
likely downregulated BCRP through an estrogen receptor
(ER), while progesterone alone upregulated BCRP via a
mechanism other than progesterone receptor (PR).
In conclusion, we found Bcrp to be present in numerous
murine endocrine organs, including ovary, pituitary gland
and adipose tissues. Furthermore, the efficient inhibition of
BCRP-mediated transport by estradiol, testosterone, proges-
terone and androstenedione implies a clear interaction be-
tween the steroids and the efflux pump. Together, our results
support the speculation that BCRP has a role in steroid
hormone regulation. Further research will address this
hypothesis.
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